The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines

Cancer Immunology, Immunotherapy

Volumn 58, Issue 5, 2009, Pages 665-675

  Sørensen, Rikke Bæk ^a   Junker, Niels ^a   Kirkin, Alexei ^a   Voigt, Heike ^b   Svane, Inge Marie ^a   Becker, Jürgen C ^b   Thor Straten, Per ^a   Andersen, Mads Hald ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Bcl 2; Cytotox T cells; Lysis; Melan A MART 1; Melanoma

Indexed keywords

HLA A2 ANTIGEN; MELAN A; PROTEIN BCL 2;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL CLONING; CELL CULTURE; CELL KILLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; EPITOPES, T-LYMPHOCYTE; GRANZYMES; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; INTERFERON-GAMMA; MELANOMA; NEOPLASM PROTEINS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PORE FORMING CYTOTOXIC PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 61349083603     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0588-0     Document Type: Article

References (32)

1. MH Andersen JE Bonfill A Neisig G Arsequell I Sondergaard G Valencia J Neefjes J Zeuthen T Elliott JS Haurum 1999 Phosphorylated peptides can be transported by TAP molecules, presented by Class I MHC molecules, and recognized by phosphopeptide-specific CTL J Immunol 163 3812 3818
2. MH Andersen LO Pedersen JC Becker P Thor Straten 2001 Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients Cancer Res 61 869 872
3. MH Andersen IM Svane P Kvistborg OJ Nielsen E Balslev S Reker JC Becker SP Thor 2005 Immunogenicity of Bcl-2 in cancer patients Blood 15 728 734
4. T Boon PG Coulie BJ Van den Eynde BP van der 2006 Human T cell responses against melanoma Annu Rev Immunol 24 175 208 175-208
5. CM Britten C Gouttefangeas MJ Welters G Pawelec S Koch C Ottensmeier A Mander S Walter A Paschen J Muller-Berghaus I Haas A Mackensen T Kollgaard SP Thor M Schmitt K Giannopoulos R Maier H Veelken C Bertinetti A Konur C Huber S Stevanovic T Wolfel SH van der Burg 2008 The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays Cancer Immunol Immunother 57 289 302
6. U Chattopadhyay 1999 Tumour immunotherapy: developments and strategies Immunol Today 20 480 482
7. AG Dalgleish MA Whelan 2006 Cancer vaccines as a therapeutic modality: the long trek Cancer Immunol Immunother 55 1025 1032
8. KA Divito AJ Berger RL Camp M Dolled-Filhart DL Rimm HM Kluger 2004 Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma Cancer Res 64 8773 8777
9. PR Dunbar JL Chen D Chao N Rust H Teisserenc GS Ogg P Romero P Weynants V Cerundolo 1999 Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma J Immunol 162 6959 6962
10. PR Dunbar CL Smith D Chao M Salio D Shepherd F Mirza M Lipp A Lanzavecchia F Sallusto A Evans R Russell-Jones AL Harris V Cerundolo 2000 A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response J Immunol 165 6644 6652
11. C Gouttefangeas A Stenzl S Stevanovic HG Rammensee 2007 Immunotherapy of renal cell carcinoma Cancer Immunol Immunother 56 117 128
12. M Griffioen M Borghi PI Schrier S Osanto D Schadendorf 2004 Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates Cancer Immunol Immunother 53 715 722
13. SD Griffiths JC Cawley 1987 The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity Leukemia 1 372 376
14. V Groh R Rhinehart J Randolph-Habecker MS Topp SR Riddell T Spies 2001 Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells Nat Immunol 2 255 260
15. G Guichard A Zerbib FA Le Gal J Hoebeke F Connan J Choppin JP Briand JG Guillet 2000 Melanoma peptide MART-1(27-35) J Med Chem 43 3803 3808
16. MR Hussein AK Haemel GS Wood 2003 Apoptosis and melanoma: molecular mechanisms J Pathol 199 275 288
17. Jager E, Hohn H, Necker A, Forster R, Karbach J, Freitag K, Neukirch C, Castelli C, Salter RD, Knuth A, Maeurer MJ (2002) Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int J Cancer 20;98:376-388
18. BL Kaplan H Norell GG Callender T Ohlum R Kiessling MI Nishimura 2006 Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells Cancer Immunol Immunother 55 653 662
19. R Kiessling E Klein H Wigzell 1975 "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype Eur J Immunol 5 112 117
20. AF Kirkin T Reichert Petersen AC Olsen L Li P Thor Straten J Zeuthen 1995 Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines Cancer Immunol Immunother 41 71 81
21. HT Maecker T Frey LE Nomura J Trotter 2004 Selecting fluorochrome conjugates for maximum sensitivity Cytometry A 62 169 173
22. S Morel F Levy O Burlet-Schiltz F Brasseur M Probst-Kepper AL Peitrequin B Monsarrat R Van Velthoven JC Cerottini T Boon JE Gairin BJ Van den Eynde 2000 Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells Immunity 12 107 117
23. RA Morgan ME Dudley JR Wunderlich MS Hughes JC Yang RM Sherry RE Royal SL Topalian US Kammula NP Restifo Z Zheng A Nahvi CR de Vries LJ Rogers-Freezer SA Mavroukakis SA Rosenberg 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 126 129
24. DR Parkinson RP Brightman SD Waksal 1981 Altered natural killer cell biology in C57BL/6 mice after leukemogenic split-dose irradiation J Immunol 126 1460 1464
25. G Pawelec SG Marsh 2006 ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank Cancer Immunol Immunother 55 623 627
26. MJ Pittet D Valmori PR Dunbar DE Speiser D Lienard F Lejeune K Fleischhauer V Cerundolo JC Cerottini P Romero 1999 High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals J Exp Med 190 705 715
27. P Romero N Gervois J Schneider P Escobar D Valmori C Pannetier A Steinle T Wolfel D Lienard V Brichard A Van Pel F Jotereau JC Cerottini 1997 Cytolytic T lymphocyte recognition of the immunodominant HLA-A0201-restricted Melan-A/MART-1 antigenic peptide in melanoma J Immunol 159 2366 2374
28. ES Schultz J Chapiro C Lurquin S Claverol O Burlet-Schiltz G Warnier V Russo S Morel F Levy T Boon BJ Van den Eynde van der BP 2002 The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome J Exp Med 195 391 399
29. RB Sorensen SR Hadrup T Kollgaard IM Svane SP Thor MH Andersen 2007 Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient Cancer Immunol Immunother 56 527 533
30. Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A, Zuber M, Luscher U, Harder F, Heberer M (1995) Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer 20;64:309-315
31. EJ Stevens L Jacknin PF Robbins Y Kawakami M el Gamil SA Rosenberg JR Yannelli 1995 Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition J Immunol 154 762 771
32. JM Teng KT Hogan 1994 Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoxic T lymphocytes Mol Immunol 31 459 470